HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome.

Abstract
Because patients who undergo allogeneic hematopoietic cell transplantation (allo-HCT) remain in the vicinity of the transplant center for approximately 90 days posttransplantation, identifying prognostic factors to determine those at immediate higher risk of mortality is essential. A normal serum albumin level generally denotes healthiness. We evaluated the prognostic significance of day 90 hypoalbuminemia (and other clinical, pharmacologic, and laboratory variables) in 163 patients, median age 48 years (range, 19-69 years), who underwent allo-HCT for acute myelogenous leukemia (n = 124) or myelodysplastic syndrome (n = 39). Day 90 hypoalbuminemia (serum albumin <3.0 g/dL) was associated with worse nonrelapse mortality (NRM) and poor overall survival (OS). The estimated 1- and 2-year cumulative incidence rates of NRM were 48% and 52%, respectively, and the corresponding OS rates were 7% and 3%. Serum albumin level <3.0 g/dL and Karnofsky score <80 at day 90 were strong independent predictors of worse NRM and OS in multivariate analysis. These results support day 90 hypoalbuminemia as an adverse prognostic marker for NRM and OS after allo-HCT for acute myelogenous leukemia and myelodysplastic syndrome.
AuthorsMohamed A Kharfan-Dabaja, Julio C Chavez, Daohai Yu, Weiwei Zhu, Eduardo I Fernandez-Vertiz, Janelle Perkins, Jamie Shapiro, Ryan Bookout, Lia Perez, Hugo F Fernandez, Rami S Komrokji, Jeffrey Lancet, Linda Brand, Teresa Field, Ernesto Ayala, William Janssen, Alan F List, Claudio Anasetti
JournalBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation (Biol Blood Marrow Transplant) Vol. 17 Issue 3 Pg. 384-93 (Mar 2011) ISSN: 1523-6536 [Electronic] United States
PMID20655389 (Publication Type: Journal Article)
CopyrightCopyright © 2011 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
Topics
  • Adult
  • Aged
  • Female
  • Hematopoietic Stem Cell Transplantation (adverse effects)
  • Humans
  • Hypoalbuminemia (blood, etiology)
  • Karnofsky Performance Status
  • Leukemia, Myeloid, Acute (diagnosis, therapy)
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes (diagnosis, therapy)
  • Prognosis
  • Retrospective Studies
  • Severity of Illness Index
  • Statistics as Topic
  • Survival Analysis
  • Time Factors
  • Transplantation, Homologous
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: